Wei Yue, Xinyu Li, Xiaolu Zhan, Lei Wang, Jihong Ma, Meiyu Bi, Qilong Wang, Xiaoyang Gu, Bingteng Xie, Tong Liu, Hongyan Guo, Xin Zhu, Chen Song, Jie Qiao, Mo Li
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as promising chemotherapeutic drugs primarily against BRCA1/2-associated tumours, known as synthetic lethality. However, recent clinical trials reported patients' survival benefits from PARP inhibitor treatments, irrelevant to homologous recombination deficiency. Therefore, revealing the therapeutic mechanism of PARP inhibitors beyond DNA damage repair is urgently needed, which can facilitate precision medicine. METHODS: A CRISPR-based knock-in technology was used to establish stable BRCA1 mutant cancer cells...
April 18, 2024: EBioMedicine